Anixa Biosciences, Inc.

Cleveland Clinic researchers present findings on a vaccine targeting triple-negative breast cancer, showing it is well-tolerated and induces immune responses. The ongoing phase 1 trial, funded by the U.S. Department of Defense, includes 26 patients across three cohorts. Anixa plans a phase 2 study to evaluate efficacy, expected to start in 2025.

CGTLive’s Weekly Rewind highlights 5 gene and cell therapy advances: CARTITUDE-4 trial outcomes, Ocugen’s phase 3 gene therapy, Anixa’s investigational new drug clearance, Epic Bio’s technology applications, and CSF analysis reductions in NAA levels.